SCHEMBL2869956

SCHEMBL2869956

CCc1ccc(Cc2ccc(Cl)c(CP(=O)(O)O)c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.40
SLC5A2 P31639 3/20 0.40
SLC5A1 P13866 2/20 0.40
PGK1 P00558 3/20 0.39
PGK2 P07205 3/20 0.39
GAA P10253 2/20 0.38
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
NLRP1 Q9C000 1/20 0.38
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CYP2C19 P33261 1/20 0.37
SRC P12931 1/20 0.36
ENPP2 Q13822 1/20 0.36
FDPS P14324 1/20 0.36
PTPN5 P54829 1/20 0.35
S1PR1 P21453 1/20 0.35
S1PR3 Q99500 1/20 0.35
HAO1 Q9UJM8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2864769 0.88 SLC5A2 (0.45) PLK1SLC5A2SLC5A1PGK1PGK2
SCHEMBL2869912 0.83 PGK1 (0.51) PLK1SLC5A2SLC5A1PGK1PGK2
SCHEMBL2868577 0.83 THRA (0.50) PLK1PGK1PGK2THRATHRB
SCHEMBL2859709 0.82 PLK1 (0.40) PLK1PGK1PGK2GAALMNA
SCHEMBL2864690 0.79 CA2 (0.45) PLK1SLC5A2SLC5A1GAALMNA
SCHEMBL2871236 0.77 SLC5A2 (0.42) SLC5A2SLC5A1GAALMNAMAPK1
SCHEMBL2869183 0.74 THRA (0.47) PLK1PGK1PGK2THRATHRB
SCHEMBL2874055 0.73 SLC5A2 (0.51) SLC5A2SLC5A1
SCHEMBL2863551 0.73 ALPG (0.44) SMN1; SMN2
SCHEMBL2869960 0.73 THRA (0.49) PLK1THRATHRBSMN1; SMN2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691898-B2 Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US disclosed
US-20080119441-A1 Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
CN-101072783-A Phosphonic acid derivative and therapeutic agent for disease in which high phosphate level in blood participates KOTOBUKI PHARMACEUTICAL CO LTD (JP) 2007-11-14 CN disclosed
EP-1813620-A1 PHOSPHONIC ACID DERIVATIVE AND THERAPEUTIC AGENT FOR DISEASE IN WHICH HIGH PHOSPHATE LEVEL IN BLOOD PARTICIPATES Kotobuki Pharmaceutical Co., Ltd. (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119441-A1 Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia NR0B1, NR0B2, PTH1R PLK1 1962/4885SLC5A2 1771/4885SLC5A1 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.